Tanya Clark-Myrick, APRN
Psychiatric/Mental Health · Cleveland, OHNPI 1285300491
Payments from drug & device makers
Across 13 payments — averaging $107.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$374
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$202
- Neurocrine Biosciences, Inc.$125
- AstraZeneca$125
- Johnson & Johnson$123
- SK Life Science, Inc.$118
- plus $325 from 4 others
What the payments were for
- Food & beverage$1,393100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $374 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $202 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| AstraZeneca | 1 | $125 |
| Johnson & Johnson | 1 | $123 |
| SK Life Science, Inc. | 1 | $118 |
| Alkermes, Inc. | 1 | $91 |
| Eisai Inc. | 1 | $85 |
| Corium, LLC | 1 | $84 |
| Biohaven Pharmaceuticals, Inc. | 1 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$374
- INGREZZA$125
- FASENRA$125
- INVEGA SUSTENNA$123
- INVEGA TRINZA$123
- XCOPRI$118
- CAPLYTA$115
How this compares
$1,393 in reported general payments places this provider in the 65th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyzine Hcl | 52 | $1,785 |
| Aripiprazole | 32 | $1,717 |
| Mirtazapine | 60 | $1,299 |
| Bupropion XlBupropion Hcl | 51 | $1,046 |
| Quetiapine Fumarate | 51 | $888 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $858 |
| Olanzapine | 28 | $612 |
| Haloperidol Decanoate | 20 | $544 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $540 |
| Fluoxetine Hcl | 46 | $531 |
| Trazodone Hcl | 94 | $492 |
| Sertraline Hcl | 58 | $465 |
| Lurasidone Hcl | 11 | $332 |
| Lamotrigine | 44 | $322 |
| Duloxetine Hcl | 17 | $291 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Cleveland
- Sarah DemkoCleveland$28K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.